Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.

@article{Paolicelli2015LongtermCS,
  title={Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.},
  author={Damiano Paolicelli and Alessia Manni and Vita Direnzo and Mariangela D'Onghia and Carla Tortorella and Stefano Zoccolella and Maria Trojano},
  journal={Journal of clinical pharmacology},
  year={2015},
  volume={55 10},
  pages={1131-6}
}
Fingolimod is the first oral disease-modifying therapy approved for multiple sclerosis (MS). The risks associated with the use of fingolimod include cardiovascular adverse events (AEs). First-dose observation (FDO) is required for all patients for at least 6 hours. We describe FDO data and long-term cardiac tolerability in a cohort of fingolimod-treated… CONTINUE READING

Topics

Statistics

020402015201620172018
Citations per Year

fewer than 50 Citations

Semantic Scholar estimates that this publication has 50 citations based on the available data.

See our FAQ for additional information.